Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERBB2 | P04626 | 19/20 | 0.43 |
| ▸ | EGFR | P00533 | 7/20 | 0.43 |
| ▸ | NQO2 | P16083 | 1/20 | 0.41 |
| ▸ | FECH | P22830 | 1/20 | 0.41 |
| ▸ | MYH14 | Q7Z406 | 1/20 | 0.41 |
| ▸ | RIPK3 | Q9Y572 | 1/20 | 0.41 |
| ▸ | MET | P08581 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22525244 | 1.00 | ERBB2 (0.43) | ERBB2EGFRNQO2FECHMYH14 | |
| SCHEMBL25572680 | 0.90 | ERBB2 (0.44) | ERBB2EGFRNQO2FECHMYH14 | |
| SCHEMBL24569571 | 0.88 | ERBB2 (0.36) | ERBB2EGFRNQO2FECHMYH14 | |
| SCHEMBL26128232 | 0.86 | ERBB2 (0.41) | ERBB2EGFRNQO2FECHMYH14 | |
| SCHEMBL30050453 | 0.86 | ERBB2 (0.42) | ERBB2EGFRNQO2FECHMYH14 | |
| SCHEMBL24167718 | 0.85 | MPO (0.35) | ERBB2EGFRNQO2FECHMYH14 | |
| SCHEMBL30613042 | 0.83 | ERBB2 (0.39) | ERBB2EGFRNQO2FECHMYH14 | |
| SCHEMBL1192195 | 0.82 | ERBB2 (0.48) | ERBB2EGFRNQO2FECHMYH14 | |
| SCHEMBL29414877 | 0.82 | ERBB2 (0.48) | ERBB2EGFRNQO2FECHMYH14 | |
| SCHEMBL25177224 | 0.82 | NR4A1 (0.36) | ERBB2EGFRNQO2FECHMYH14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4587124-A1 | POLYCYCLIC QUINAZOLINES FOR INHIBITION OF ERBB2 | Enliven Inc. (US) | 2025-07-23 | — | — | EP | disclosed |
| WO-2024229019-A1 | POLYMORPHIC FORMS OF (E)-L-((10S)-4-((4-([L,2,4]TRIAZOLO[L,5-A]PYRIDIN- 7-YLOXY)-2-FLUORO-5-METHYLPHENYL)AMINO)-7,8,10,LL-TETRAHYDRO- 9H-6,10-METHANOPYRIMIDO[4',5':5,6]PYRIDO[3,2-B][L,4,7]OXADIAZONIN-9- YL)-4-(DIMETHYLAMINO)BUT-2-EN-L-ONE | ENLIVEN INC. (US) | 2024-11-07 | — | — | WO | disclosed |
| EP-4426697-A1 | FUSED TETRACYCLIC QUINAZOLINE DERIVATIVES AS INHIBITORS OF ERBB2 | Enliven Inc. (US) | 2024-09-11 | — | — | EP | disclosed |
| CN-118103370-A | Fused tetracyclic quinazoline derivatives as ERBB2 inhibitors | 英莱汶公司 | 2024-05-28 | — | — | CN | disclosed |
| WO-2024059558-A1 | POLYCYCLIC QUINAZOLINES FOR INHIBITION OF ERBB2 | ENLIVEN INC. (US) | 2024-03-21 | — | — | WO | disclosed |
| EP-4267137-A1 | LACTAM (HETERO)ARYLFUSEDPYRIMIDINE DERIVATIVES AS INHIBITORS OF ERBB2 | Enliven Inc. (US) | 2023-11-01 | — | — | EP | disclosed |
| WO-2023077259-A1 | FUSED TETRACYCLIC QUINAZOLINE DERIVATIVES AS INHIBITORS OF ERBB2 | ENLIVEN THERAPEUTICS, INC. (US) | 2023-05-11 | — | — | WO | disclosed |
| WO-2023081637-A1 | FUSED TETRACYCLIC QUINAZOLINE DERIVATIVES AS INHIBITORS OF ERBB2 | ENLIVEN THERAPEUTICS, INC. (US) | 2023-05-11 | — | — | WO | disclosed |
| WO-2022140769-A1 | LACTAM (HETERO)ARYLFUSEDPYRIMIDINE DERIVATIVES AS INHIBITORS OF ERBB2 | ENLIVEN THERAPEUTICS, INC. (US) | 2022-06-30 | — | — | WO | disclosed |